ADC Therapeutics is a clinical-stage oncology drug discovery and development company focused on advancing highly targeted antibody drug conjugates (ADCs) for the treatment of hematological cancers and solid tumors. Our proprietary ADCs are developed using the latest-generation pyrrolobenzodiazepine (PBD) dimer platform. PBD dimers are very potent toxins that actively kill cancer cells and have a different mechanism of action than warheads commonly used in other ADCs.